BACKGROUND: The purpose of this study was to identify usefulness of 1-year of thyroid stimulating hormone (TSH) suppression, on additional levothyroxine in patients who underwent hemithyroidectomy with papillary thyroid microcarcinoma (PTMC). METHODS: Two-hundred consecutive patients who had received hemithyroidectomy February 2011 to March 2013, were enrolled, retrospectively. Group 1, only, was taking levothyroxine for a year, postoperatively. We evaluated postoperative hypothyroidism through serum TSH level, measured periodically. RESULTS: Postoperative TSH >10 was significantly different, at 13% and 25%, between two groups (P=0.036). Twenty patients in group 1, and 32 patients in group 2, received additional levothyroxine. Multivariate analysis showed that 1-year suppression, clinical thyroiditis, and preoperative TSH >2, were significantly associated with additional levothyroxine (OR 2.17, P=0.025 and OR 2.00, P=0.046 and OR 2.64, P=0.006). Too, 1-year TSH suppression, preoperative TSH >2, were also significantly associated with postoperative TSH >10 (OR 2.55, P=0.022 and OR 2.22, P=0.048). CONCLUSIONS: We suggest 1-year TSH suppression after hemithyroidectomy, for PTMC in patients with preoperative TSH >2 mU/L and clinical thyroiditis, to reduce additional levothyroxine. 2019 Gland Surgery. All rights reserved.
BACKGROUND: The purpose of this study was to identify usefulness of 1-year of thyroid stimulating hormone (TSH) suppression, on additional levothyroxine in patients who underwent hemithyroidectomy with papillary thyroid microcarcinoma (PTMC). METHODS: Two-hundred consecutive patients who had received hemithyroidectomy February 2011 to March 2013, were enrolled, retrospectively. Group 1, only, was taking levothyroxine for a year, postoperatively. We evaluated postoperative hypothyroidism through serum TSH level, measured periodically. RESULTS: Postoperative TSH >10 was significantly different, at 13% and 25%, between two groups (P=0.036). Twenty patients in group 1, and 32 patients in group 2, received additional levothyroxine. Multivariate analysis showed that 1-year suppression, clinical thyroiditis, and preoperative TSH >2, were significantly associated with additional levothyroxine (OR 2.17, P=0.025 and OR 2.00, P=0.046 and OR 2.64, P=0.006). Too, 1-year TSH suppression, preoperative TSH >2, were also significantly associated with postoperative TSH >10 (OR 2.55, P=0.022 and OR 2.22, P=0.048). CONCLUSIONS: We suggest 1-year TSH suppression after hemithyroidectomy, for PTMC in patients with preoperative TSH >2 mU/L and clinical thyroiditis, to reduce additional levothyroxine. 2019 Gland Surgery. All rights reserved.
Authors: Herman Verloop; Marloes Louwerens; Jan W Schoones; Job Kievit; Johannes W A Smit; Olaf M Dekkers Journal: J Clin Endocrinol Metab Date: 2012-04-17 Impact factor: 5.958
Authors: Donald S A McLeod; Karen F Watters; Anthony D Carpenter; Paul W Ladenson; David S Cooper; Eric L Ding Journal: J Clin Endocrinol Metab Date: 2012-05-23 Impact factor: 5.958
Authors: Amanda Johner; Obi L Griffith; Blair Walker; Leanne Wood; Hannah Piper; Graeme Wilkins; Christopher Baliski; Steven J M Jones; Sam M Wiseman Journal: Ann Surg Oncol Date: 2011-03-10 Impact factor: 5.344
Authors: Tae Kwun Ha; Dong Wook Kim; Ha Kyoung Park; Jin Wook Baek; Yoo Jin Lee; Young Mi Park; Do Hun Kim; Soo Jin Jung; Ki Jung Ahn Journal: Int J Endocrinol Date: 2016-05-11 Impact factor: 3.257